Symbol="SPRY"
AssetType="Common Stock"
Name="Silverback Therapeutics Inc"
Description="ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California."
CIK="1671858"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="500 FAIRVIEW AVENUE NORTH, SUITE 600, SEATTLE, WA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="668022000"
EBITDA="-59987000"
PERatio="None"
PEGRatio="None"
BookValue="2.607"
DividendPerShare="0"
DividendYield="0"
EPS="-0.59"
RevenuePerShareTTM="0.003"
ProfitMargin="0"
OperatingMarginTTM="-275.49"
ReturnOnAssetsTTM="-0.247"
ReturnOnEquityTTM="-0.38"
RevenueTTM="219000"
GrossProfitTTM="1316000"
DilutedEPSTTM="-0.59"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.978"
AnalystTargetPrice="14"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="329.69"
PriceToBookRatio="-"
EVToRevenue="264.76"
EVToEBITDA="-26.57"
Beta="None"
num_52WeekHigh="9.65"
num_52WeekLow="3.99"
num_50DayMovingAverage="6.76"
num_200DayMovingAverage="7.09"
SharesOutstanding="95568000"
DividendDate="None"
ExDividendDate="None"
symbol="SPRY"
open="6.96"
high="7.05"
low="6.88"
price="6.90"
volume="176194.00"
latest_trading_day="2023-08-24"
previous_close="6.99"
change="-0.09"
change_percent="-1.2876%"
aroon_positive_momentum_days="62"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="TRUE"
Aroon_momentum="62"
Volume_recent_avg="1180193"
Change_recent_avg="-0.02"
Delta_recent_avg="0.46"
Variance_recent_avg="0.23"
Change_ratio_recent_avg="-0.48"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="positive"
Aroon_change="TRUE"
Aroon_momentum_positive="62"
Aroon_momentum_negative="38"
image_negative_thumbnail_id_1="1155"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0189.jpeg"
image_negative_thumbnail_id_2="146"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0030.jpeg"
image_neutral_thumbnail_id_1="522"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0077.jpeg"
image_neutral_thumbnail_id_2="582"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0017.jpeg"
image_positive_thumbnail_id_1="992"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0154.jpeg"
image_positive_thumbnail_id_2="702"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0006.jpeg"
image_professor_thumbnail_id_1="1179"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
image_professor_thumbnail_id_2="1193"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
